TearScience, has completed a $44.5 million of Series C funding from new investors.
TearScience, has completed a $44.5 million of Series C funding from new investors. The monies will allow TearScience to commercialize its devices designed to diagnose and treat the most common form of chronic dry eye disease.
TearScience's technology provides the most significant advancement in the past few decades toward the treatment of patients with evaporative dry eye problems, said Dr Alan N. Carlson, professor of ophthalmology and chief of the Corneal and Refractive Surgery Service at Duke Eye Centre. We have an enormous number of patients who are frustrated with their chronic dry eye condition. TearScience clinical results show that the therapy offers the 'game changer' we have been waiting for.
